Treatment of postoperative atrial fibrillation: The long road ahead

Dawn S. Hui, MD, and Richard Lee, MD, MBA

During the past few decades, there have been numerous advances in the surgical treatment of atrial fibrillation (AF), with well-established, evidence-based recommendations. Contrast this with the treatment of postoperative AF (POAF) following cardiac surgery: The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guideline, which included input from a Heart Association/American College of Cardiology/American Thoracic Society/American College of Surgeons (ATS)/Society of Thoracic Surgeons (STS), adds only that apixaban and edoxaban may be equitable alternatives to warfarin in patients with AF and undergoing cardiac surgery, the recently published 2019 guideline update, endorsed by the Society of Thoracic Surgeons (STS), that converts to sinus rhythm is transient in nature. A few brief statements on POAF for cardiac and thoracic surgery: beta-blockade and calcium channel blockers are Class I recommendations, whereas prophylactic amiodarone, ibutilide, or direct current cardioversion; maintenance with antiarrhythmic medications; antithrombotic medications; and rate control/anticoagulation/cardioversion are all Class II recommendations described as reasonable therapies. These did not markedly differ from the 2006 guidelines. Regarding patients undergoing cardiac surgery, the recently published 2019 guideline update, endorsed by the Society of Thoracic Surgeons (STS), adds only that apixaban and edoxaban may be equitable alternatives to warfarin in patients with AF and remote bioprosthetic valve implantations, and that further study is needed before recommending use of the Congestive heart failure, Hypertension, Age, Diabetes, and Stroke/Transient Ischemic Attack Vascular Disease (CHA2DS2-VASc) score in this population. On POAF, no new recommendations have come forth. A natural question is why there is such disparity between advancements in the monitoring and treatment after surgical treatment of AF, but not of AF after surgical treatment of other cardiac lesions.

There are several potential etiologies of this discrepancy. First, POAF has historically been characterized as low in incidence, transient in nature, and benign in course. However, one should consider the context in which it is assessed. Because POAF falls in the bucket of postoperative complications, data on its true prevalence may be limited with reportable postoperative metrics typically limited to a 30-day period. This problem may be compounded by the limits of detection. With increasing scrutiny of hospital stay as quality metric, shorter postoperative stays mean shorter monitoring periods and the possibility of underestimating POAF. One cannot see that for which one does not look. There is also a perception that in-hospital–detected POAF that converts to sinus rhythm is transient in nature. A few studies using contemporary monitoring modalities during the postdischarge period suggest that this perception might benefit from re-examination. A small study by Funk and colleagues, utilizing ambulatory symptom-linked event recorders plus daily transmitted electrocardiograms, found the in-hospital rate of AF to be 28% but the overall postoperative rate to be 42%. After hospital discharge, 14% of patients had AF episodes, with the first episode occurring after postoperative day 5 in >10% of patients. Another study using continuous ambulatory monitoring for 80 hours postoperatively found sustained (ie, lasting >10 minutes) POAF in 40% of postcoronary artery bypass grafting (CABG) patients. These hypothesis-generating findings have not translated into more extensive study nor use of longer-term monitoring in contemporary studies.

The idea that POAF is benign in course is reflected in the following sentence from a 2003 study: “Although postoperative AF usually does not result in long-term sequelae, it often increases length and cost of hospital stay due to hemodynamic compromise or thromboembolic
complications.” Recent data challenge the first part of this statement. New-onset POAF was a significant predictor not only of long-term AF, with a 5-fold higher incidence, but also of mortality at 3.5 years’ follow-up in a propensity score analysis of isolated CABG patients. Post-hoc analysis of the Evaluation of the Xience versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial found that new-onset POAF incurred a 4-fold risk of stroke (adjusted hazard ratio [aHR], 4.19; 95% confidence interval [CI], 1.74-10.11). New-onset POAF was also associated with worse mortality at 30-days (odds ratio [OR], 5.0; 95% CI, 14-18) and 1-year (aHR, 2.2; 95% CI, 1.2-3.9) in an international multicenter study of 28 programs, and with death at 3 years in the EXCEL trial (aHR, 3.02; 95% CI, 1.6-5.70).

Even with limited monitoring characterizing recent studies, POAF incidence seems to be increasing. After isolated CABG, in-hospital AF was 28% in the STS multicenter Contemporary Analysis of Perioperative Cardiovascular Surgical Care Registry. The overall rate in a randomized trial was 30% and nearly 50% in those undergoing combined CABG/valve procedures. That these rates are several-fold higher than prior studies may reflect changes in the complexity of the operative procedures and patient comorbidities, including obesity, which confers a substantially greater POAF burden. Thus, the problem of POAF is one that cardiothoracic surgical community should reconsider, particularly in light of its association with long-term stroke and mortality.

Future Directions: Opportunities

Opportunities exist to begin addressing these many knowledge gaps in POAF by using tools already in use for the detection and management of AF. First, accurate data regarding the true incidence will be necessary to define the scope of the problem. This brings its own set of questions: What is the period of risk, and does it differ between those who experience early versus late POAF? Answering this question may require continuous ambulatory monitoring. Whether the costs of such devices will be covered is 1 issue, and the optimal duration of monitoring and patient compliance are 2 others. Edgerton and colleagues suggested that 7-days’ monitoring after ablation of AF was ideal, but the optimal monitoring period after cardiac surgery without ablation has not been defined. Evolving developments in wearable technology may represent an opportunity for more convenient ambulatory monitoring but need further validation of their accuracy. Patients with existing cardiac devices represent an opportunity to study the incidence of POAF by routinely interrogating such devices postoperatively. However, such patients will certainly represent a selection bias.

The other 3 opportunities are prevention, risk stratification, and treatment. In the current guidelines, the only Class I recommendation for prevention of POAF is preoperative beta-blocker therapy. An analysis of the data for this recommendation suggests newer analysis may be needed. The primary citation was a 2004 Cochrane review of 28 randomized controlled trials on beta-blocker use, and there has since been a 2013 updated review. In the reviews, the outcome of interest was not AF alone but rather a combination of AF and supraventricular tachycardia. Half of the studies used propranolol, and most remarkably, 82% began the beta-blocker treatment postoperatively. Further, both reviews found significant heterogeneity across studies ($I^2 = 64$ and 55, respectively). This is a quality metric that continues to be debated. A survey by the Society of Cardiovascular Anesthesiology (SCA) and European Association of Cardiothoracic Anaesthetists (EACTA) found that 36% followed this guideline “Sometimes” and 43% “Nearly always.” Reported barriers to use were “Risk outweighs benefit” in >50% of EACTA respondents and about one third of SCA respondents; “Bradycardia risk” and “Do not believe it has a benefit” were the next highest reasons. These concerns about safety and efficacy have been raised in the recent literature. A meta-analysis of isolated CABG studies found that preoperative beta-blocker use was associated with a significant increase in the incidence of POAF (OR, 1.08; 94% CI, 1.06-1.10; $P < .001$), whereas a statewide database using propensity matched STS data of patients undergoing aortic valve replacement found preoperative beta-blocker associated with significantly increased POAF, as well as other morbidities of cardiac arrest, renal failure requiring dialysis, and postoperative transfusion.

Amiodarone is a Class IIA recommendation for prophylaxis, but there was even greater concern about the risk-benefit ratio in the SCA/EACTA survey. The 2013 Cochrane review of 33 studies similarly found significant heterogeneity ($I^2 = 63$) and that half of studies began administration postoperatively. Other measures for primary prevention included magnesium, statins, and colchicine, among many others. The uncertainty regarding efficacy of prophylaxis is reflected in the wide variation in implementation of POAF protocols. Until cardiac surgeons and anesthesiologists have the evidence to support confidence in the safety and efficacy of these adjunctive therapies, adoption will, and perhaps should, remain low.

Risk stratification may aid surgeons in choosing patients in whom the benefit of prophylactic measures might outweigh the risks. As previously discussed, the 2019 focused update deemed there to be insufficient evidence for utilization of CHA2DS2-VASc score in patients with AF and remote bioprosthetic valve implantation. A small study ($N = 277$) of isolated CABG, valve, or CABG/value...
patients found that new-onset POAF was independently predicted by CHADS2 (OR, 1.54) and CHA2DS2-VASc (OR, 1.63) scores; Kaplan-Meier analysis showed a cutoff of 2 for both scoring systems. This finding was replicated in a study of 518 patients undergoing valvular surgery, with an incremental increase in POAF with as scores increased (area under the curve, 0.821 for CHADS2 and 0.765 for CHA2DS2-VASc). Notably, AF was defined by hospitalization, telemetry, or echocardiogram within 30 days, not continuous monitoring. Nevertheless, POAF rates were 30% in the first study and 45% in the latter, which found no difference in POAF incidence by valve operation type (ie, aortic vs mitral vs tricuspid). Other studies have concluded that current scoring systems are moderate at best and that better predictive models are needed.

Scoring systems also do not correlate with prescribing practices. In the Contemporary Analysis of Perioperative Cardiovascular Surgical Care registry, there was a generally high prevalence of CHADS2 score ≥2, which was significantly greater in those with POAF (81% vs 75%; P = .001). Only 39% of those with POAF were prescribed warfarin at discharge, although warfarin data were missing in 43% of the cohort. In the EXCEL trial, oral anticoagulation was prescribed in only 10.1% of patients who developed POAF, also consisting of warfarin exclusively. Perhaps it was believed that, in the 85.8% of patients who had resolved AF by the time of discharge, recurrence would be low. It is also quite possible that lack of long-term monitoring and anticoagulation could explain the higher long-term stroke rates in POAF patients, rather than simply risk factors. Whether novel oral anticoagulants (NOACs), with standard dosing and absence of monitoring needs, will lead to greater prescribing practices and compliance remains to be seen. The eventual approval of reversal agents may also lead to greater comfort with prescribing NOACs. However, there are numerous reasons for continued caution. These include the higher risk of major bleeding with only 2 doses of dabigatran compared with warfarin in patients aged ≥75 years. Increased major pericardial bleeding with NOACs versus warfarin in the Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etepliril in Patients after Heart Valve Replacement trial, and limitations in patients with renal dysfunction such as contraindicated or altered dosing and generally higher bleeding risk.

Future Directions: The Challenges

The current thinking on POAF is demonstrated by what is among the few randomized, controlled trials of patients with this condition, in which the primary outcome was the total number of hospital days within 60 days after randomization to a rate versus rhythm control strategy. This end point may have allowed the investigators to accrue a sufficient sample with implications for short-term management. In the context of the clinical outcomes we have just discussed, it may be time for studies to take a different approach. However, several challenges exist. A hurdle to defining incidence is the burden of postdischarge monitoring. For detecting AF in general, remote monitoring has a 95% sensitivity, but the question of cost and optimal monitoring duration remain. Costs associated with remote monitoring include not only the device itself, but also administrative resources such as trained personnel for rhythm interpretation, generation and communication of reports, and data entry into the medical records. However, as bundled payments move toward a longer 90-day global period, this cost may be offset by the benefit of earlier identifying and managing POAF before it triggers symptom-related readmissions or thromboembolic events. Taking an even longer-term view, there are data suggesting that outpatient monitoring is cost-effective for patients, providers, and health care systems. The second challenge is to improve the level of evidence. Even if studies with longer continuous monitoring demonstrate a higher incidence of short- to midterm POAF, there is clearly minimal effect; short-term stroke rates appear to be low as demonstrated by current identification and management strategies. Therefore, it may not be feasible to adequately design clinical trials that will meaningfully change current clinical practice.

We propose a reconceptualization of POAF. Contemporar-
References


